Physician profile
David R Repaske
NPI 1861420986
$50,508.75
in general payments reported to CMS, 2019-2025
10 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2022: $50.00 · 2023: $4,156 · 2024: $6,261 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Consulting Fee: $15K · Food and Beverage: $2,641 · Travel and Lodging: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,301.25 |
| Consulting Fee | $14,714.00 |
| Food and Beverage | $2,640.95 |
| Travel and Lodging | $2,474.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $44,285.98 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $3,300.00 | 2025 | Acp-101 |
| Catalyst Pharmaceuticals, INC. | $1,989.65 | 2024 | |
| Ascendis Pharma Endocrinology INC | $370.28 | 2024-2025 | |
| Novo Nordisk INC | $223.81 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $153.84 | 2019 | |
| Tolmar, INC. | $114.47 | 2024 | |
| Biomarin Pharmaceutical INC. | $70.72 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Repaske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.